Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000323778 | SCV000344027 | uncertain significance | not provided | 2016-08-04 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001216693 | SCV001388503 | uncertain significance | Facioscapulohumeral muscular dystrophy 2 | 2024-03-13 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 1016 of the SMCHD1 protein (p.Pro1016Leu). This variant is present in population databases (rs528154864, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with SMCHD1-related conditions. ClinVar contains an entry for this variant (Variation ID: 289638). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004021285 | SCV004954124 | uncertain significance | Inborn genetic diseases | 2023-12-13 | criteria provided, single submitter | clinical testing | The c.3047C>T (p.P1016L) alteration is located in exon 24 (coding exon 24) of the SMCHD1 gene. This alteration results from a C to T substitution at nucleotide position 3047, causing the proline (P) at amino acid position 1016 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |